Takeda Pharmaceutical
TAK
$13.19
Share price
0.23%
Change (1 day)
-21.07%
Change (1 year)
Categories
Operating Margin for Takeda Pharmaceutical (TAK)
Operating Margin as of April 2024 (TTM): 14.33%
According to Takeda Pharmaceutical's latest financial reports and stock price the company's current Operating Margin is 14.33%. At the end of 2023 the company had an Operating Margin of 9.31%.
Operating Margin history for Takeda Pharmaceutical from 2009 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2023 | 9.31% | 9.86% |
| 2022 | 8.48% | -25.98% |
| 2021 | 11.45% | -720.42% |
| 2020 | -1.85% | -140.8% |
| 2019 | 4.52% | -63.12% |
| 2018 | 12.27% | 48.23% |
| 2017 | 8.28% | 24.09% |
| 2016 | 6.67% | -181.53% |
| 2015 | -8.18% | -187.12% |
| 2014 | 9.39% | 12.74% |
| 2013 | 8.33% | -50.22% |
| 2012 | 16.73% | -36.08% |
| 2011 | 26.18% | -7.71% |
| 2010 | 28.37% | 9.49% |
| 2009 | 25.91% | -38.25% |
| 2008 | 41.96% | -12.43% |
| 2007 | 47.92% | 12.14% |
| 2006 | 42.73% | 8.78% |
| 2005 | 39.28% | -4.35% |
| 2004 | 41.07% | -0.54% |
| 2003 | 41.29% | 11.12% |
| 2002 | 37.15% | 36.07% |
| 2001 | 27.30% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 22.88% | 59.67% | 🇺🇸 USA |
 Novartis NVS | 17.27% | 20.52% | 🇨🇭 Switzerland |
 Pfizer PFE | 34.61% | 141.52% | 🇺🇸 USA |
 Amgen AMGN | 34.59% | 141.38% | 🇺🇸 USA |
 Sanofi SNY | 18.21% | 27.08% | 🇫🇷 France |
 Merck MRK | 27.73% | 93.51% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 22.54% | 57.29% | 🇬🇧 UK |
 Seagen
SGEN | -30.69% | -314.17% | 🇺🇸 USA |
 Dr. Reddy's RDY | 24.69% | 72.30% | 🇮🇳 India |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.